Industry
Biotechnology
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Insights
March 19, 2024 | 9:25 pm
Portfolio Pulse from Benzinga Newsdesk
November 13, 2023 | 9:57 pm
Portfolio Pulse from Benzinga Insights
November 13, 2023 | 11:40 am
Portfolio Pulse from Benzinga Insights
November 10, 2023 | 5:02 pm
Portfolio Pulse from vinayak@benzinga.com
August 14, 2023 | 8:48 pm
Portfolio Pulse from Benzinga Insights
June 22, 2023 | 3:02 pm
Portfolio Pulse from richadhand@benzinga.com
June 22, 2023 | 11:16 am
Portfolio Pulse from Nabaparna Bhattacharya
June 21, 2023 | 3:40 pm
Portfolio Pulse from Happy Mohamed
June 21, 2023 | 12:42 pm
Portfolio Pulse from Happy Mohamed
June 21, 2023 | 12:16 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.